E7-8870. New Animal Drugs; Change of Sponsor's Name and Address  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's name from American Pharmaceutical Partners, Inc., to Abraxis Pharmaceuticals Products and to change the sponsor's mailing address.

    DATES:

    This rule is effective May 9, 2007.Start Printed Page 26289

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: david.newkirk@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    American Pharmaceuticals Partners, Inc., 2045 North Cornell Ave., Melrose Park, IL 60160, has informed FDA of a change of name and mailing address to Abraxis Pharmaceutical Products, a Div. of Abraxis Bioscience, 6133 River Rd., suite 500, Rosemont, Il 60018. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c) to reflect these changes.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects in 21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

    End Amendment Part Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority Start Amendment Part

    2. Section 510.600 is amended in the table in paragraph (c)(1) by removing the entry for “American Pharmaceuticals Partners, Inc.” and alphabetically adding a new entry for “Abraxis Pharmaceutical Products”; and in the table in paragraph (c)(2) by revising the entry for “063323” to read as follows:

    End Amendment Part
    Names, addresses, and drug labeler codes of sponsors of approved applications.
    * * * * *

    (c) * * *

    (1) * * *

    Firm name and addressDrug labeler code
    *    *    *    *    *
    Abraxis Pharmaceutical Products, a Div. of Abraxis Bioscience, 6133 River Rd., suite 500, Rosemont, IL 60018063323
    *    *    *    *    *

    (2) * * *

    Drug labeler codeFirm name and address
    *    *    *    *    *
    063323Abraxis Pharmaceutical Products, a Div. of Abraxis Bioscience, 6133 River Rd., suite 500, Rosemont, IL 60018
    *    *    *    *    *
    Start Signature

    Dated: May 1, 2007.

    Bernadette Dunham,

    Deputy Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. E7-8870 Filed 5-8-07; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
5/9/2007
Published:
05/09/2007
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
E7-8870
Dates:
This rule is effective May 9, 2007.
Pages:
26288-26289 (2 pages)
Topics:
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements
PDF File:
e7-8870.pdf
CFR: (1)
21 CFR 510.600